# Boutique Venture Partners

> Boutique Venture Partners is a VC fund in Palo Alto backing Health Care and Medical. See 37 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 37
- Last investment: Feb 2026
- Lead investor: 14%
- Last fund: May 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/boutique-venture-partners/
- Website: https://www.boutiquevc.com/

Boutique Venture Partners is a VC fund in Palo Alto focused on Health Care and Medical. Boutique Venture Partners focuses on emerging healthcare and life science solutions to make a significant impact at scale. We are a team of hardcore scientists and clinicians who partner with outstanding founders to create innovative and disruptive approaches that improve health and wellness. We leverage our deep connections with the healthcareecosystem to get early access to innovations and discoveries coming out of premiere academic institutes and industry. We pay particular attention to early-stage companies that are (i) developing novel approaches/platforms with solid IP, (ii) founded by authentic entrepreneurs with deep domain expertise, and (iii) having large growth potential while demonstrating societal impact. At Boutique, our team of top-tier scientists and business leaders work closely with portfolio companies to launch the next generation of transformative technologies.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.5M–$5.7M |
| Pre-Seed | $1.8M–$2.6M |
| Series A | $4M–$31M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 32% |
| Medical | 6 | 16% |
| Biotechnology | 6 | 16% |
| Medical Device | 5 | 14% |
| Artificial Intelligence | 5 | 14% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 12 | 32% |
| Series A | 7 | 19% |
| Pre-Seed | 3 | 8% |
| Series B | 2 | 5% |
| Funding Round | 2 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 35% |
| Canada | 2 | 5% |
| France | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Handl Health | Handl Health is a technology platform transforming how health plans are evaluated, designed and managed. By unifying healthcare pricing, utilization, benefit and quality data into a single analytical and operational layer, Handl empowers brokers, carriers and third-party administrators to build flexible, cost-effective health benefits. Handl’stechnology delivers the infrastructure, analytics and insights needed to power the next generation of alternative health plans. | $14.2M | Series A | Feb 23, 2026 |  |
| Ventaris Surgical | Ventaris Surgical is a medical equipment company that provides surgical instruments to specialists. | $30.7M | Series A | Jan 09, 2026 |  |
| Smartlens | Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $5.2M | Venture - Series Unknown | Oct 14, 2025 |  |
| Delfina | Delfina provides a personalized prenatal care system that uses the power of data to keep moms and babies safe during pregnancy. Their data-driven approach is uncovering unique insights in prenatal care to pave the way for clinical innovation. | $17M | Series A | Jan 28, 2025 |  |
| Handl Health | Handl Health is a technology platform transforming how health plans are evaluated, designed and managed. By unifying healthcare pricing, utilization, benefit and quality data into a single analytical and operational layer, Handl empowers brokers, carriers and third-party administrators to build flexible, cost-effective health benefits. Handl’stechnology delivers the infrastructure, analytics and insights needed to power the next generation of alternative health plans. | $2.5M | Seed | Apr 24, 2024 |  |
| Surge | Surge is an immunological model capable of predicting postoperative infections. The company combines a single-cell assessment of the immune system before surgery with clinical data using a proprietary machine-learning algorithm. By analyzing the millions of immune cells in a small amount of blood, the platform can mimic surgical trauma in a testtube before surgery. | $5.7M | Seed | Mar 27, 2024 |  |
| FluidAI Medical | FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $14.6M | Series A | Oct 10, 2023 |  |
| FluidAI Medical | FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $15M | Series A | Oct 10, 2023 |  |
| Mitra Chem | Mitra Chem operates as a lithium-ion battery materials manufacturer. It innovates and commercializes iron-based cathode materials to enable mass-market electrification in transportation and energy storage. The company is driven to industrialize these cathodes in purpose-built inflation reduction act-compliant facilities. | $40M | Series B | Aug 16, 2023 |  |
| Smartlens | Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $6.1M | Series A | Jul 11, 2023 |  |

10 of 37 investments shown.

## Co-investors
- [Graphene Ventures](https://shizune.co/investors/profile/graphene-ventures) — VC Fund, 7 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 7 deals together
- [Berkeley Catalyst Fund (BCF)](https://shizune.co/investors/profile/berkeley-catalyst-fund-bcf) — VC Fund, 6 deals together
- [DOV Management](https://shizune.co/investors/profile/d-one-vision-management) — VC Fund, 6 deals together
- [Syensqo Ventures](https://shizune.co/investors/profile/solvay-ventures) — VC Fund, 5 deals together
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Medical Device Investors](https://shizune.co/investors/medical-device-investors)
- [Medical Device VC Funds](https://shizune.co/investors/medical-device-vc-funds)
- [Medical Device VC Funds in United States](https://shizune.co/investors/medical-device-vc-funds-united-states)
- [Medical Device Investors in United States](https://shizune.co/investors/medical-device-investors-united-states)
- [Medical Device VC Funds in Canada](https://shizune.co/investors/medical-device-vc-funds-canada)
- [Machine Learning VC Funds in France](https://shizune.co/investors/machine-learning-vc-funds-france)

## FAQ

### What does Boutique Venture Partners invest in?

Boutique Venture Partners invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Boutique Venture Partners's check size?

Boutique Venture Partners typically joins rounds of $2.5M–$5.7M at Seed, $1.8M–$2.6M at Pre-Seed and $4M–$31M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boutique Venture Partners participates in.

### When did Boutique Venture Partners last invest?

The most recent investment recorded for Boutique Venture Partners closed in Feb 2026. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co